| Code | CSB-RA023615MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar referenced to the antibody described in patent US 11,208,495 B2, targeting TM4SF1 (transmembrane 4 L six family member 1), also known as L6 or tumor-associated antigen L6. TM4SF1 is a cell surface glycoprotein with four transmembrane domains that regulates cell motility, proliferation, and signal transduction. While weakly expressed in normal tissues, TM4SF1 is highly overexpressed in multiple epithelial malignancies including lung, breast, colon, ovarian, pancreatic, prostate, and gastric cancers. In endothelial cells, TM4SF1 is critical for filopodia formation, cell migration, and tumor angiogenesis through interactions with integrins and activation of VEGF signaling pathways. TM4SF1 promotes epithelial-mesenchymal transition, cancer stem cell characteristics, and metastasis through AKT and β-catenin signaling. The reference antibody targets the extracellular loop-2 domain of TM4SF1 for cancer therapeutic applications. This biosimilar provides researchers with a valuable tool for investigating TM4SF1-mediated tumor progression, studying endothelial cell function and pathological angiogenesis, and exploring dual-target strategies addressing both tumor cells and tumor vasculature. It supports research into antibody-dependent cellular cytotoxicity mechanisms, CAR-T cell therapy development, and the role of TM4SF1 in chemotherapy resistance.
There are currently no reviews for this product.